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Is there a (host) genetic
predisposition to progressive
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Progressivemultifocal leukoencephalopathy (PML) has been described in association with
a variety of predisposing risk factors, including HIV/AIDS, lymphoproliferative disorders
and, most recently, treatment with a range of biologics, most notably natalizumab in
multiple sclerosis (MS) (1). However, while these underlying disorders appear to be
(usually) necessary, they are not sufficient to predict the development of PML, since only
a small fraction of such individuals will succumb, raising the question of whether host
genetic factors must also play a role. Evidence is mounting that this is, indeed, the case
but more work needs to be done to fully delineate these underlying genetic factors. Finally,
while it is possible that an underlying genetic susceptibility for PML in general will be
uncovered in the future, the current evidence argues for a collection of multiple, individually
rare underlying susceptibilities (with one predominant single genetic susceptibility in each
individual), as described in this review.
Keywords: progressive multifocal leukoencephalopathy, host genetic factors, primary immunodeficiencies, PML
predisposition, natalizumab
Introduction
Progressive multifocal leukoencephalopathy (PML) is a severe, potentially fatal, CNS infection. It is
“caused” by reactivation of the JC virus (JCV). However, while JCV is present at very high rates in
the general population, PML remains a rare disorder, albeit an important one because of the clinical
sequelae, and the recently demonstrated association with a variety of useful therapies, in particular
natalizumab in multiple sclerosis (MS). A number of risk factors for PML have been described but
these are better viewed as necessary but not sufficient. The majority of individuals with these risk
factors do not develop PML and so the obvious question is “In addition to the well-known risk factors
for PML, are there host genetic factors that also play a role?”
“Traditional” Risk Factors for PML
This is a topic that has been well reviewed in the literature [for a recent comprehensive discussion,
see Ref. (1)]. In brief, while rare individuals have been reported, in whom no obvious risk factors
are present (2), the majority of individuals have a history of profound cellular immunosuppression,
whether associated with systemic disorders, such as HIV, lymphoproliferative disease, rheumatolog-
ical disorders (SLE, for example), or else treatment with immunosuppressive or immunomodulatory
therapies. Historically, PML (first described in the 1950s) was known mainly as a disease associated
with lymphoproliferative disorders. Knowledge of PML increased with the advent of AIDS, as 4–5%
of patients developed PML. In recent years, PML has come to prominence in the context of the
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drug natalizumab, an effective biologic used in the treatment
of MS. PML has also been described in association with other
biologics [reviewed in Ref. (1)] and, most recently, with the use
of drugs containing fumarates (used in the treatment of psoriasis
and also the MS drug Tecfidera) (3).
The important point is that while these risk factors are highly
relevant, they do not, on their own, predict who will develop
PML, since the vast majority of individuals with these risk factors
will not develop the disorder. Clearly, other factors need to be
considered and there is growing evidence for the role of host
genetic factors in susceptibility to PML.
Finally, the rare description of individuals that have developed
PML in the complete absence of any known “traditional” risk
factor argues very strongly for the presence of host genetic factors
that result in an inability to effectively deal with JCV.
Precedents for Genetic Predisposition to
Specific Infectious Disease
Many factors/conditions are known to predispose to infectious
disease in general. However, what is of greater interest is the
existence of genetic syndromes that appear to predispose to
severe infection with very specific infectious agents. A classical
example is X-linked lymphoproliferative syndrome (XLP), a pri-
mary immunodeficiency disorder (PID) characterized by severe
immune dysregulation often after viral infection, typically with
Epstein–Barr virus (EBV). XLP is present in two forms, each
associated with mutations in a different gene: XLP1 is associated
with SH2D1A mutations, while XLP2 is associated with XIAP
mutations. Both genes are located in Xq25 (4). More recently,
Herpes simplex virus encephalitis (HSE), a rare complication
of infection with HSV-1 has been shown to be associated with
deficiency of TLR3 at 4q35.1 (5).
Known/Suspected Genetic Predispositions
for PML
The association of PML with rare immune deficiency syndromes
is suggested by a number of case reports, some of which predated
the ability to confirm the clinical diagnosis of the underlying
disorder by specific gene testing.
Table 1 summarizes specific PIDs in which PML has been
reported, along with estimates for the numbers of distinct PML
cases observed.
Wiskott–Aldrich Syndrome
Wiskott–Aldrich syndrome (WAS) is an X-linked recessive
immunodeficiency, caused by mutations in the WAS gene at
Xp11.23. A similar disorder, WAS2, is caused by recessive muta-
tions in WIPF11, at 2q31.1. There are five reports of PML in
association with clinically diagnosedWAS. It is unclear whyWAS
is the most common PID described in association with PML. This
may simply be due to ascertainment bias, given that the small
number of cases reported early on may have alerted clinicians to
specifically test for this condition. Alternatively, this may simply
be a sampling issue, given the rarity of PML.
TABLE 1 | Summary of specific PIDs reported in association with PML.
Disorder predisposing to PML Gene Number
PML cases
Reference
Wiskott–Aldrich Syndrome WAS, WIPF11 5 (6–10)
Severe combined
immunodeficiency syndrome
Various 2 (11, 12)
X-linked hyper-IgM Syndrome CD40LG 3 (13–15)
Hyper IgE Syndrome DOCK8, STAT3,
TYK2, STK3
2 (16, 17)
ICF syndrome DNMT3B 1 (18)
Adenosine deaminase deficiency ADA 1 (19)
Idiopathic CD4 deficiency RAG1, MST1,
LCK, ITK
1 (20)
X-linked agammaglobulinemia BTK 1 (21)
Purine nucleoside phosphorylase
deficiency
PNP 1 (22)
STAT1 gain of function STAT1 1 (23)
Note that references refer to PML case reports but genes listed refer to known causes of
the syndrome, even if some specific genes have not yet been implicated in PML per se.
Severe Combined Immunodeficiency Syndrome
Severe combined immunodeficiency syndrome (SCID) refers to
a genetically and clinically heterogeneous group of disorders with
defective cellular and humoral immune function. There have been
at least two reports of PML in association with SCID.
X-Linked Hyper-IgM Syndrome
X-Linked Hyper-IgM Syndrome is caused by mutations in the
CD40LG (aka TNFSF5) gene at Xq26.3. It is a rare immunodefi-
ciency characterized by normal/elevated IgM levels but markedly
decreased IgG, IgA, and IgE resulting in a profound susceptibility
to bacterial infections and an increased susceptibility to oppor-
tunistic infections. It has been described in four patients reported
as having PML.
Hyper-IgE Syndrome
Hyper-IgE recurrent infection syndrome is a PID characterized
by chronic eczema, recurrent staphylococcal infections, increased
serum IgE, and eosinophilia. It may be associated with dominant
mutations in STAT3 at 17q21.2, recessive mutations in DOCK8
at 9p24.3, or recessive mutations in TYK2 at 19p13.2 (only one
case reported). Most recently, a patient with PML was reported
with a >500 kb homozygous deletion encompassing a number of
genes in 9p24.3, with DOCK8 the strongest candidate for PML
susceptibility. Finally, there was also a report of a patient with PML
associated with DOCK8 mutation in 2010.
ICF syndrome
Immunodeficiency, Centromeric instability, and Facial dysmor-
phism (ICF) syndrome is a rare autosomal recessive syndrome
associated with mutations in DNMT3B at 20q11.21. One PML
case has been reported in a patient with ICF.
Adenosine Deaminase Deficiency
Inherited Adenosine Deaminase (ADA) deficiency causes a spec-
trum of disease, from SCID, presenting in infancy and usually
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resulting in early death, to a later onset at age 6–24months, and,
finally, a small percentage of cases with a “later” onset, presenting
from 4 years of age to adulthood. The disorder is associated with
mutations in ADA at 20q13.12. There has been one case of PML
reported in the context of ADA deficiency.
Idiopathic CD4 Deficiency
Idiopathic CD4 lymphocytopenia (ICL) is a syndrome described
in patients with low counts of CD4 cells and no other causes for
immunosuppression. A few cases of PML have been described in
association with this entity. Mutations in a number of genes have
been reported in association with ICL, including RAG1 at 11p.12,
MST1 at 3p21.31, LCK at 1p35.1, and ITK at 5q33.3. One case of
PML has been reported in association with ICL.
X-Linked Agammaglobulinemia
X-linked agammaglobulinemia (XLA) is caused by mutations
in the BTK gene at Xq22.1. It results in an immunodeficiency
characterized by failure to produce mature B lymphocytes and is
associatedwith a failure of Ig heavy chain rearrangement.One case
of PML has been reported in association with XLA.
Purine Nucleoside Phosphorylase Deficiency
Purine nucleoside phosphorylase (PNP) deficiency is a rare auto-
somal recessive immunodeficiency disorder characterized mainly
by decreased T cell function. It is caused by mutations in the PNP
gene at 14q11.2 One case has been reported with PML.
STAT1 Gain of Function
Mutations in STAT1 (2q32.2) have been implicated in a number
of disorders, including susceptibility to a variety of infectious
agents, depending on which of four main subtypes of STAT1 is
present. In one study describing the association between STAT
gain of function mutations and disseminated coccidioidomycosis
and histoplasmosis, one of five patients was reported with PML.
Challenges of Genetic Studies into PML
While the reports of rare individuals with PML in association
with a confirmed PID immediately suggest a set of candidate
genes that should be routinely searched for in PML patients, even
when no such obvious (clinical) diagnosis has been made, it is
possible that a more subtle and specific immunodeficiency will
explain the majority of cases of PML, namely an immunodefi-
ciency that is not clinically recognizable except in the context of
JCV (i.e., one that does not result in other opportunistic infec-
tions, as is the case for XLP and specific susceptibility to EBV,
or has other obvious associated clinical features that would lead
to a diagnosis of a known PID). However, it is important to
note that precedents do exist for the role of Mendelian genes,
initially identified in severe disorders, being relevant to general
populations in whom the severe phenotype is not present. An
example of this has recently been demonstrated in late-onset
Alzheimer’s disease (LOAD), with the finding that rare variants in
PSEN1, PSEN2, andAPP increase the risk ofAlzheimer’s in LOAD
families.
While a candidate gene list presents itself, there do remain
significant challenges for the genetic dissection of PML predis-
position, not only because the examples of PIDs described in
association with PML are likely to account for only a small subset
of the overall susceptibility to this disorder but because of more
general considerations.
Progressive multifocal leukoencephalopathy remains an
uncommon disorder, whose geographical distribution is wide.
Very few specialists/centers have seen more than a handful of
cases and collecting samples from sufficient numbers of cases has
been challenging. Furthermore, based on the number of distinct
PIDs in which PML has been reported in at least some cases, it
is likely that the number of genes that might predispose to PML
is significant, so that the unbiased identification of rare, causal
variants will prove very difficult using modern whole genome
or exome sequencing methods, for example, since the degree of
background variation is simply too great to achieve statistical
significance. The challenge of using next generation sequencing
approaches is exacerbated by the possibility that some mutations
may be dominantly acting (i.e., heterozygotes have the genetic
susceptibility), a class of variants for which inferring causality is
much more challenging than recessive disorders. Furthermore,
the usual “tricks” employed to find significant causal variants
in human genetic disorders either via traditional approaches or
using NGS cannot be used because:
There are no:
1. families with Mendelian inheritance of PML (useful for tra-
ditional linkage analysis and/or segregation analysis of vari-
ants in suspected candidate genes), since, even were a domi-
nant mutation to be segregating, it is highly unlikely that all
carriers would also have the other, requisite, predispositions
(underlying cellular immune suppression of whatever cause,
for example);
2. obvious examples of PML arising as a result of a de novomuta-
tion [in some childhood syndromes, such as severe intellectual
disability (where parents are phenotypically normal), searches
for de novo mutations have been fruitful];
3. other clinical/phenotypic clues that may aid in delineation of
more specific subsets, for which correlations with underlying
genetics may be useful (as occurs frequently in ID, wherein
many ID syndromes are associated with specific physical man-
ifestations that permit more specific disease delineation).
Discovery of the set of variants that underlie predisposition to
PML is likely to depend on a combination of
1. consideration of strong candidate genes, in addition to those
linked to already described PIDs. However, this is still a large
class, based on the high number of genetically distinct condi-
tions that are associated with immune suppression;
2. unbiased, genome-wide searches for causal variants, coupled
with intelligent filtering of variants, based on known PIDs
along with gene function as related to the immune sys-
tem. However, such genome-wide searches for novel variants
underlying PML development will not be straightforward;
3. the use of larger cohorts of PML subjects than has hitherto been
possible.
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Potential Benefits of Uncovering Genetic
PML-Susceptibility Variants
In the short term, the ability to more accurately predict who is
at high risk of developing PML will be of enormous benefit in the
context of drug treatment with compounds (mostly biologics) that
are highly effective in their disease context (natalizumab inMS, for
example) but carry a small risk of a devastating disorder. The hope
is that patients in whom a course of treatment is being planned
with such a drug would undergo initial, companion diagnostic
testing, in order to effectively exclude those that were at high risk
of PML, in the process reassuring those with negative tests about
their dramatically reduced risk of developing PML.
Currently, the only approach in this direction is based on testing
for the presence of JCV, since JCV is an absolute pre-requisite for
PMLdevelopment (24).However, because JCV is present in a large
percentage of the normal population, this approach effectively
excludes a significant proportion of patients from a treatment that
is highly effective. In fact, it is possible that testing for JCV virus
will not achieve its stated aim and patients will elect to accept
the risk of PML, in return for improved quality of life on drug
treatment (e.g., natalizumab in MS).
Conclusion
There appear to be threemajor criteria thatmust be fulfilled before
PML occurs:
1. JCV is present;
2. some form of cellular immune suppression is present, whether
due to underlying systemic disease (such as hematological
malignancy) or treatment with immunosuppressives (espe-
cially biologics, such as natalizumab);
3. host (genetic) susceptibility to develop PML;
For those rare individuals in whom no specific immune sup-
pression is present in the medical history, there are two probably
only essential factors:
1. JCV is present;
2. host (genetic) susceptibility to develop PML.
While there has been good progress in unraveling the epidemi-
ology of PML, there is now some urgency to uncover as many
of the underlying genetic variants as possible, primarily to create
an effective and specific screening test that will determine, as
definitively as possible, which patients should not be treated with
a given therapeutic (MS, for example, when natalizumab is being
considered) and which patients can safely (with dramatically
reduced risk) be treated.
Finally, an improved understanding of the etiology of PMLmay,
in the longer term, provide insights that will lead to therapies for
individuals in whomPMLhas arisen as a result of their underlying
disease, rather than a chosen treatment (e.g., HIV/AIDS and
lymphoproliferative disorders).
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